Free Trial
NYSE:KVUE

Kenvue Q3 2025 Prepared Remarks Earnings Results & Report

Kenvue logo
$18.66 +0.66 (+3.64%)
Closing price 10/15/2026 03:59 PM Eastern
Extended Trading
$18.68 +0.02 (+0.09%)
As of 05:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kenvue beat analyst earnings expectations but missed on revenue in its Q3 2025 Prepared Remarks results, released November 3, 2025. The company reported EPS of $0.28 versus the $0.27 consensus estimate, while revenue of $3.76 billion fell short of the $3.83 billion estimate by $64.88 million. Revenue decreased 3.5% year over year.

Earnings Announcement Details

Quarter
Q3 2025 Prepared Remarks
Report Date
Time
Before Market Opens
Conference Call
6:00 AM ET

Kenvue EPS Results

Actual EPS
$0.28
Consensus EPS
$0.27
Beat/Miss
Beat by +$0.01
One Year Ago EPS
$0.28
EPS Beat Rate
6 of last 8 quarters

Kenvue Revenue Results

Actual Revenue
$3.76 billion
Expected Revenue
$3.83 billion
Beat/Miss
Missed by -$64.88 million
YoY Revenue Growth
-3.50%

Upcoming Earnings

Kenvue's Q3 2026 earnings is estimated for Monday, November 2, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Kenvue Q3 2025 Prepared Remarks Earnings FAQ

Kenvue (NYSE:KVUE) reported earnings of $0.28 per share for Q3 2025 Prepared Remarks, beating the consensus estimate of $0.27. The report was announced on Monday, November 3, 2025.

Kenvue reported revenue of $3.76 billion for Q3 2025 Prepared Remarks, against a consensus estimate of $3.83 billion.

Kenvue's next earnings date is estimated for Monday, November 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Kenvue on the company's earnings history page.

Kenvue Earnings Headlines

Citi Keeps Their Hold Rating on Kenvue, Inc. (KVUE)
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing December 8th.tc pixel
See More Kenvue Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kenvue? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kenvue and other key companies, straight to your email.

About Kenvue

Kenvue (NYSE:KVUE) (NYSE: KVUE) is a consumer health company that develops, markets and sells self-care, skin health and essential health products. Its portfolio includes over-the-counter medicines, allergy and cold remedies, pain-relief products, oral-care items, wound-care products, baby care products and beauty brands.

Kenvue’s principal brands include Tylenol, Motrin, Zyrtec, Benadryl, Neutrogena, Aveeno, Listerine, Johnson’s and BAND-AID. The company distributes its products through pharmacies, retailers, e-commerce channels, healthcare providers and other commercial outlets in markets around the world.

Kenvue was formed through the separation of Johnson & Johnson’s consumer health business and became an independent publicly traded company in 2023. The company is headquartered in Skillman, New Jersey, and serves consumers across a broad range of geographic markets. Its leadership is focused on expanding its established brand portfolio and developing consumer health products intended for everyday use.

View Kenvue Profile